In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bob Kronemyer

Advertisement
Set Alert for Articles By Bob Kronemyer

Latest From Bob Kronemyer

Market Intel: Large Providers Focus On Hemodialysis Home Care; New Incentive By Presidential Executive Order

Momentum is rising for patients with chronic kidney disease to be treated with hemodialysis in the comfort of their own home as opposed to traveling several days a week to a freestanding clinic. Manufacturers, government and payers are paving the way for a higher home-therapy adoption rate. That said, many patients remain unsuitable for home care and the large volume of water needed to operate hemodialysis can be logistically daunting.

Market Intelligence Renal

Start-Up Spotlight: Innovative Cardiovascular Solutions Hopes To Win Regulatory Nod For Embolic Protector For TAVR

Transcatheter aortic valve replacement (TAVR) is performed routinely using devices providing protection from stroke as standard of care. However, cerebral embolic protection devices currently available do not capture and remove emboli from all three vessels leading to the brain. The Emblok Embolic Protection System from Innovative Cardiovascular Solutions (ICS) has developed an embolic filter designed to protect all three cerebral vessels during TAVR and remove debris from the entire circulatory system.

Commercial Start-up Spotlight

Market Intel: Liquid Biopsy – Ready For Prime Time?

Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.

Commercial Innovation

Start-Up Spotlight: Small Lens In Eardrum Hopes To Make Big Soundwaves In Hearing Aid Market

A new hearing aid lets users enjoy the full range of normal hearing frequencies, activated by a contact lens on the eardrum. The hearing aid from Earlens Corp. also provides audio gain without feedback. In October, the company completed an $87m round of financing, which will help launch its next-generation hearing aid, which employs magnetic induction for further hearing refinement.

Start-up Spotlight StartUps and SMEs

Market Intel: Cornea, Bio-Drugs, Artificial Hips On Track For 3D Printing

Although certainly not a given, many researchers and companies are pursing the eventual goal of bioprinting human organs, starting with the three-dimensional printing of a structure that has cellular function. If organ function via bioprinting becomes a reality for the skin, bone, lung, liver, eye and/or kidney, among other potential organs, the market opportunity could be in the billions. But challenges, including cost and ethics, stand in the way of this milestone in regenerative medicine.

Regenerative Medicine Market Intelligence

Start-Up Spotlight: Bay Labs' AI Technology Paves Way To Retailer Echo Testing

In an effort to make cardiac imaging more accessible and to lead to more appropriate diagnosis of cardiac disease, Bay Labs Inc. is developing software algorithms designed to allow echocardiography to be performed by non-specialists in echo, including medical providers such as nurses and physician assistants. The backbone of the technology is artificial intelligence (AI), specifically deep-learning algorithms.

Cardiovascular Commercial
See All
Advertisement
UsernamePublicRestriction

Register